Abstract
The drug release profiles of poly(dimer acid-dodecanedioic acid) P(DA-DDDA) copolymer containing 5% adriamycin hydrochloride (ADM) in vitro were evaluated. The biocompatibility of P(DA-DDDA) under mice skin was also evaluated, macroscopic observation and microscopic analysis demonstrated that the copolymer is biocompatible and well tolerated in vivo. Antitumor efficacy of P(DA-DDDA) copolymers containing 5% adriamycin hydrochloride (ADM) implanted subcutaneously in mice bearing Sarcoma-180 tumor exhibited increased volume doubling time (VDT) (31 +/- 1.5 days) compared to plain subcutaneous injection of ADM (7 +/- 0.9 days). The studies suggest that P(DA-DDDA) copolymer as an effective carrier for antineoplastic drug like adriamycin hydrochloride has a very good prospect in the treatment of noumenon tumors.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / chemistry
-
Antibiotics, Antineoplastic / pharmacokinetics
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Delayed-Action Preparations / administration & dosage*
-
Delayed-Action Preparations / chemistry
-
Delayed-Action Preparations / pharmacokinetics
-
Dicarboxylic Acids / administration & dosage*
-
Dicarboxylic Acids / chemistry
-
Dicarboxylic Acids / pharmacokinetics
-
Diffusion
-
Doxorubicin / administration & dosage*
-
Doxorubicin / chemistry
-
Doxorubicin / pharmacokinetics
-
Drug Compounding / methods
-
Drug Implants
-
Injections, Subcutaneous
-
Materials Testing
-
Mice
-
Polymers / administration & dosage*
-
Polymers / chemistry
-
Polymers / pharmacokinetics
-
Sarcoma / drug therapy*
-
Sarcoma / pathology*
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Delayed-Action Preparations
-
Dicarboxylic Acids
-
Drug Implants
-
Polymers
-
poly(dimer acid-dodecanedioic acid) copolymer
-
Doxorubicin